The Effect of Sildenafil on Sleep-Disordered Breathing in Obese Patients With Sexual Dysfunction

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2009 by Assaf-Harofeh Medical Center.
Recruitment status was  Recruiting
Information provided by:
Assaf-Harofeh Medical Center Identifier:
First received: May 3, 2009
Last updated: May 4, 2009
Last verified: May 2009

Sildenafil has been shown to aggravate sleep-disordered breathing in patients with severe obstructive sleep apnea. The aim of the present study is to examine the frequency of sleep-disordered breathing in obese patients who are candidates for treatment with sildenafil for sexual dysfunction. In addition we wish to assess the effect of sildenafil on sleep-disordered breathing.

Sleep Apnea
Sexual Dysfunction

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Effect of Sildenafil on Sleep-Disordered Breathing in Obese Patients With Sexual Dysfunction

Resource links provided by NLM:

Further study details as provided by Assaf-Harofeh Medical Center:

Primary Outcome Measures:
  • apnea hypopnea index after sildenafil vs. placebo [ Time Frame: Hours ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Sleep parameters (latency, efficiency etc) following sildenafil vs. placebo [ Time Frame: hours ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: May 2009
Treated with 50 mg of Sildenafil at night
Treated with placebo at night


Ages Eligible for Study:   40 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

50 healthy males aged 40 - 65 years


Inclusion Criteria:

  • Age - 40-65 years
  • BMI equal to or over 30

Exclusion Criteria:

  • A known cardiorespiratory, liver or kidney disease
  • Treatment with nitrates or alfa blockers
  • Performed polysomnography in the past
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00893191

Contact: Isaac Shpiree, MD 972-8-9779024
Contact: Arnon Elizur, MD 972-8-9779817

Asaf Harofeh Medical Center Recruiting
Zerifin, Israel, 70300
Principal Investigator: Isaac Shpirer, MD         
Sub-Investigator: Yoram I Siegel, MD         
Sub-Investigator: Arnon Elizur, MD         
Sponsors and Collaborators
Assaf-Harofeh Medical Center
  More Information

No publications provided

Responsible Party: Isaac Shpirer, Asaf Harofeh Medical Center Identifier: NCT00893191     History of Changes
Other Study ID Numbers: 39/09
Study First Received: May 3, 2009
Last Updated: May 4, 2009
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Therapeutic Uses
Urological Agents
Vasodilator Agents processed this record on October 02, 2015